Herboxidiene, as a potent antitumor agent, can target the SF3B subunit of the spliceosome. Herboxidiene also induces both G1 and G2/M cell cycle arrest in a human normal fibroblast cell line WI-38.[1].
In vitro, herboxidiene showed cytotoxicity with IC50 of 0.0037 to approximately 0.99 μM against human tumor cell lines, while herboxidiene were not active against both gram-positive and -negative bacteria.[3] in addition, Herboxidiene has cytotoxicity against A431, A549, and DLD-1 cells with IC50s of 3.7, 21, 51 nM, respectively.[6] In vitro efficacy test it shown that in a dose-response assay, 0.5 μM Herboxidiene had substantial inhibitory effects on the plant growth and development comparable to those of 1 μM pladienolide B.[2] In vitro, treatment with herboxidiene at 5 μM had an effect on cell and nuclei shape, suggesting there is a cellular toxicity at high concentrations.[4] In addition, herboxidiene (a less potent, structurally different splicing modulator) at 20?nM (～3 × GI50) in HCT116 cells has the possibility of resistant clone generation.[5] Herboxidiene has a cytostaticity against human umbilical vein endothelial cells with IC50 of 26 nM and has inhibition with VEGF-induced invasion and tube formation of serum-starved HUVECs in a concentration-dependent manner[7].
In vivo experiment it exhibited that treatment with 1 mg/kg herboxidiene intraperitoneally once shown obvious antitumor activity[6].
References:
[1]Ghosh AK, et al. Design and synthesis of herboxidiene derivatives that potently inhibit in vitro splicing. Org Biomol Chem. 2021 Feb 18;19(6):1365-1377.
[2]AlShareef S, et al. Herboxidiene triggers splicing repression and abiotic stress responses in plants. BMC Genomics. 2017 Mar 27;18(1):260.
[3]Sakai Y, et al. GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. I. Taxonomy, production, isolation, physicochemical properties and biological activities. J Antibiot (Tokyo). 2002 Oct;55(10):855-62.
[4]Granatosky EA, et al. GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts. J Nat Prod. 2018 Sep 28;81(9):2018-2025.
[5]Teng T, et al. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex. Nat Commun. 2017 May 25;8:15522.
[6]Miller-Wideman M, et al. Herboxidiene, a new herbicidal substance from Streptomyces chromofuscus A7847. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992 Jun;45(6):914-21.
[7]Jung HJ, et al. Antiangiogenic activity of herboxidiene via downregulation of vascular endothelial growth factor receptor-2 and hypoxia-inducible factor-1α. Arch Pharm Res. 2015 Sep;38(9):1728-35.
Herboxidiene 作为一种有效的抗肿瘤剂，可以靶向剪接体的 SF3B 亚基。在人正常成纤维细胞系 WI-38 中，Herboxidiene 还诱导 G1 和 G2/M 细胞周期停滞。[1]。
在体外，herboxidiene 对人类肿瘤细胞系表现出细胞毒性，IC50 为 0.0037 至约 0.99 μM，而 herboxidiene 对革兰氏阳性和阴性细菌均无活性。[ 3] 此外，Herboxidiene 对 A431、A549 和 DLD-1 细胞具有细胞毒性，IC50 分别为 3.7、21、51 nM。[6]< /sup> 体外药效试验表明，在剂量反应试验中，0.5 μM Herboxidiene 对植物生长发育的抑制作用与 1 μM pladienolide B 相当。[2] 在在体外，用 5 μM herboxoxidene 处理对细胞和细胞核形状有影响，表明在高浓度下存在细胞毒性。[4] 此外，herboxidiene（一种效力较低、结构不同的剪接调节剂) 20 nM (~3 × GI50) 在HCT116细胞中有产生抗性克隆的可能性。[5] Herboxidiene对人脐带有细胞生长抑制作用l 静脉内皮细胞，IC50 为 26 nM，以浓度依赖性方式抑制 VEGF 诱导的血清饥饿 HUVEC 的侵袭和管腔形成[7]。
体内实验表明，1 mg/kg herboxoxidiene腹腔注射一次显示出明显的抗肿瘤活性[6]。